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RESEARCH ARTICLE
Is there a correlation between the size of the BCG scar and renal scar of urinary tract 
infections in children?
Çocuklarda idrar yolu enfeksiyonu sonrası gelişen renal skar ile BCG skarı boyutu arasında bir 
ilişki var mıdır?
Salih Kavukçu1, Demet Alaygut1, Belde Kasap1, Alper Soylu1, Gamze Çapakaya2, Mehmet Türkmen1
ÖZET
Amaç: Pyelonefrit böbreklerde hücre ölümü ve skar geli-
şimine neden olmaktadır. Bu çalışmanın amacı, idrar yolu 
enfeksiyonu geçiren çocuklarda oluşan renal skar ile BCG 
skar boyutu arasında herhangi bir korelasyon olup olma-
dığını göstermektir. Bir korelasyon bulunması durumunda 
BCG skarı idrar yolu enfeksiyonu sonrası gelişen renal 
skarda belirleyici bir marker olarak kullanılabilecektir.
Yöntemler: En az 4 ay önce idrar yolu enfeksiyonu geçir-
miş, 99mTcDMSA sintigrafisi çekilmiş olan çocuk hastalar 
bu çalışmaya alındı Çalışma grubundaki hastaların BCG 
skarı vertikal ve horizontal çapta ölçüldü. İstatistiksel ana-
liz için en büyük çap dikkate alındı ve ≤5 mm ve >5 mm 
olarak iki gruba ayrıldı. Hastalar renal skarı olanlar (Grup 
1) ve renal skar geliştirmeyenler (Grup 2) olmak üzere iki 
grupta toplandı. Her iki grup, BCG skar boyutu ≤5 mm 
veya >5 mm olan gruplar ile karşılaştırıldı.
Bulgular: 108 (82 kız) hasta çalışmaya dahil edildi. DM-
SA’da skar olan toplam 51 hasta vardı. Skarı olan ve ol-
mayan hastaların ortalama yaşları farklı değildi. (p=0,414) 
Renal  skar  bulunan  ve  bulunmayan  gruplar  arasında 
BCG skar boyutu bakımından istatistiksel olarak anlamlı 
bir fark bulunmadı (p>0,05).
Tartışma: İdrar yolu enfeksiyonu geçiren çocuklarda re-
nal skar gelişimi ile BCG skar boyutu arasında bir kore-
lasyon bulunmadı. 
Anahtar kelimeler: BCG skarı, renal skar, idrar yolu en-
feksiyonu, çocuklar
ABSTRACT
Objective: Pyelonephritis cause cellular death, and de-
velopment of scars in kidneys. The aim of this study is to 
demonstrate a correlation (if any) between renal scar, and 
size of the scar induced by BCG vaccine in children who 
had experienced urinary tract infections. In case of detec-
tion of any correlation, BCG scar formation can be used 
as a determinative marker of renal scars, which develop 
following urinary tract infection.
Methods: Patients with a history of urinary tract infection 
at least 4 months old who had undergone    99mTcDMSA 
scanning were included in this study. Vertical and hori-
zontal diameters of BCG scars of the patients in the study 
group were measured. For statistical analysis the greatest 
diameter was taken into consideration, and the patients 
were divided into 2 subgroups based on the greatest di-
ameter of their BCG scars (Subgroups 1, ≤5 mm, and 2, 
>5 mm). The patients were also evaluated in 2 groups 
as those with (Group 1) or without (Group 2) scars. Both 
groups were compared with subgroups with the largest 
scar diameters of ≤ 5mm or >5 mm
Results:  Study  population  included  108  (82  girls)  pa-
tients.  DMSA  detected  scars  in  a  total  of  51  patients. 
Mean ages of the patients with and without scars were not 
different (p=0.414). No significant difference was found in 
size of the BCG scars between renal scar positive and 
negative groups (p>0.05).
Conclusion: No correlation was found between develop-
ment of renal scar and the size of BCG scar in children 
after urinary tract infection. J Clin Exp Invest 2013; 4 (1): 
8-12
Key words: BCG scar, renal scar, urinary tract infection, 
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INTRODUCTION
Pyelonephritis can cause programmed cell death, 
and scar development in kidneys. Apoptotic cells 
secrete profibrogenic, and inflammatory cytokines 
such as transforming growth factor beta (TGF-β), 
and tumor necrosis factor alfa (TNF-α) leading to 
the  development  of  renal  parenchymal  damage, 
and scar formation.1 It is possible to detect renal 
cortical  scar  using  99mTcDMSA  scanning.2  Bacille 
Calmette-Guerin (BCG) has been used extensively 
as a vaccine against human tuberculosis for over 
70 years. In addition to its role as a vaccine against 
tuberculosis, BCG vaccine has also been used as 
an immunotherapeutic agent by intravesical instilla-
tion in superficial cancer of the bladder.3,4 Pediatric 
tuberculosis (TB) should be accepted as a public-
health  emergency,  because  young  children  have 
a much higher risk of developing severe and fatal 
disease than adult cases. The Turkish Ministry of 
Health started a routine national immunization pro-
gram in order to prevent TB since 1953. In 1990’s 
two doses of BCG were administered in children, 
the first within 2 months of birth and the second 
at the age of 7 years, and in 2006, a single dose 
is started to be administered at 2 months of age.5 
Following vaccination, a local scar develops on the 
injection site via cellular immunity.6 Predominantly 
interferon  gamma  (IFN-  γ  ),  and  other  cytokines 
such as TNF-α and IL-2 type 1 are secreted by both 
CD4+ and CD8+ T cells which involve in the devel-
opment of scars.7
The aim of this study is to reveal a correlation (if 
any) between renal scar development after urinary 
tract infection and the size of the BCG scar. There-
fore, in case of a correlation, presence, and size of 
a BCG can be used as an important determinative 
marker for the development of renal scar.
METHODS
Medical files of children between the ages 0-18 who 
undergone upper urinary tract infection (acute py-
elonephritis) and were followed-up in Dokuz Eylül 
University Faculty of Medicine, Department of Pe-
diatric Nephrology were retrospectively examined. 
Local ethics committee approval was obtained for 
the study. Patients were selected due to their past 
medical records, and the following parameters were 
considered for the acute pyelonephritis diagnosis at 
least 4 months ago: presence of high fever, positive 
indirect tests of inflammation [elevated peripheral 
white blood cell (WBC) count, elevated C-reactive 
protein  (CRP)].  Another  selection  criteria  for  the 
study  patients  was  whether  they  had  undergone 
99mTcDMSA  scanning.  Number  of  pyelonephritis 
and the etiologic factors were ignored. BCG scars 
number and BCG scar measurement were detect-
ed. All patients had at least one, and many had 2 
BCG scars. Both vertical and horizontal diameters 
of the BCG scars were measured by the same per-
son.  Exclusion  criteria  were  suspicious  or  lower 
tract urinary infections and lack of scintigraphic ex-
amination of patients. Following parameters were 
recorded: age, gender, the presence of renal scar 
with 99mTcDMSA scanning, the presence and num-
ber of BCG scars; both vertical and horizontal diam-
eters of the BCG scar as millimeters. For statisti-
cal analysis, the greatest diameter was taken into 
consideration, and the patients were divided into 2 
subgroups based on the greatest diameter of their 
BCG scars (Groups 1, ≤ 5 mm, and 2, >5 mm). The 
patients were also evaluated in 2 groups as those 
with (Group 1) or without (Group 2) scars.
Data  were  analyzed  with  Chi-square  test, 
Mann- Whitney U test and correlation tests (Pear-
son  and  Spearman)  to  detect  the  differences  or 
relationships between the parameters using SPSS 
(version 15.0) software program. Statistical signifi-
cance was specified as p<0.05.
RESULTS
Study  population  included  108  (82  girls,  75.9%) 
patients. Mean age of the patients were 87±58 (6-
216) months. DMSA scanning detected scars in 51 
(47.2%) patients. 75 patient (69.4%) had one BCG 
scar. Mean ages of the patients with and without 
scars were not different (p=0.414). No statistically 
significant intergroup differences were found in size 
of BCG scars between renal scar positive and neg-
ative groups (Table 1).
Because, girls constituted most of the patient 
population,  intragroup  comparative  evaluations  of 
male and female cases was not performed (Table 
2, 3)
In all patient groups, correlation analysis was 
used to find relationships between variables. As a 
result, age was found to significantly positively cor-
related with horizontal diameter of BCG scar (r = 
0.525, p<0.001), vertical diameter of BCG scar (r 
= 0.05, p< 0.001) and numbers of BCG scars (r = 
0.492, p<0.001). These results are shown in Table 
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Table 1. General characteristics of the patients with and 
without scars
DMSA*
Scar (+)
DMSA*
Scar (-)
p
Age (months) 84.2 ± 60.3 75.1 ± 56.5 0.414
Sex (female/male) 33/ 18 49 / 8 0.010
BCG scar size (mm)** 4.6 ± 2.6 5.1 ± 2.3 0.357
BCG scar size 
≤ 5mm**/>5 mm** (n)
33/13 31/16 0.834
* Pyelonephritic scar as detected by  99mTcDMSA scan-
ning, ** As measured from the longest diameter of the 
scar
Table 2. Renal scar positivity, and its correlation with BCG 
scars in male patients
Male
DMSA
Scar (+)*
DMSA
Scar (-) p
BCG Scar size (mm)** 4.5 ± 2.6 3.8 ± 1.6 0.546
BCG scar size
≤ 5 mm**/ > 5 mm** (n)
11/6 6/1 0.625
*Pyelonephritic scar as detected by 99mTcDMSA scanning
**As measured from the longest diameter of the scar
Table  3:  Renal  scar  positivity,  and  its  correlation  with 
BCG scars in female patients
Female
DMSA
Scar (+)*
DMSA
Scar (-) p
BCG Scar size (mm)** 4.7 ± 2.5 5.3 ± 2.3 0.305
BCG Scar <= 5/ > 5 (n) 22/7 22/15 0.489
*Pyelonephritic scar as detected by 99mTcDMSA scanning
**As measured from the longest diameter of the scar
Table 4. Correlation between age, horizontal and vertical 
diameter and number of BCG scars
Parameters Age
r value p value
Horizontal diameter of BCG 0,525 <0.001
Vertical diameter of BCG 0,500 <0.001
Numbers of BCG 0,492 <0.001
DISCUSSION
Scar is defined as proliferation of avascular con-
nective  tissue  rich  in  collagen  fibers  developed 
following cutaneous and visceral organ inflamma-
tion.8 Scars develop because of some complex in-
teractions between cells, and cytokines. Especially, 
CD4 + T cells, and TGFβ producing T cells play im-
portant roles. As a profibrogenic mediator, the ex-
pressions of TGFβ increases mostly in all organs 
affected by the development of fibrosis. TGFβ re-
leased by many cell types including epithelial cells, 
macrophages, and myofibroblasts. Secreted TGFβ 
is inactive, and it undergoes proteolysis and con-
formational changes by the action of integrin, and 
thromboposdin.9 TGFβ regulates cell proliferation, 
differentiation,  apoptosis,  and  immune  responses 
involved in extracellular matrix turnover. These two 
basic cell types and mediators involve in both devel-
opment of dermal scar after BCG vaccination, and 
scar occurrence after renal inflammation.
BCG  vaccine  is  a  Mycobacterium  bovis  strain, 
which is transformed into a nonvirulent form carry-
ing structural characteristics of the tuberculosis ba-
cilli. It protects us from tuberculosis, and infections 
caused  by  other  atypical  mycobacterial  strains.10 
BCG vaccine activates T lymphocytes, and macro-
phages to develop an immune response.11 Within 
3-6 weeks, an ulcerated papillary lesion develops 
on this region, and a scar as a result of cell-mediat-
ed immune response.10 Studies investigating new-
borns after vaccinations, performed within the first 
months of life, have demonstrated scar formation 
within the first 6 postnatal months.12 The authors re-
ported that scars do not form when immune system 
of the infants is not fully mature, and in cases of 
vaccination performed using an improper technique 
or an impotent vaccine.13 At least one BCG scar was 
present in our entire patient group, and none of our 
patients was immunosuppressed. A positive corre-
lation was found between age and horizontal and 
vertical diameter of BCG scars in this study. This 
situation can be explained by maturation of the im-
mune system with increasing age. At the same time 
age was correlated significantly with the number of 
BCG scars. The reason for this can be done only 
single dose vaccine at 2 months of age after the 
year 2006. Therefore, older children had more of 
one vaccine.
A local inflammatory response is elicited when 
attenuated live tuberculosis vaccine is injected in-
tradermally. As epidermal  macrophages,  dendritic 
cells present this antigen to CD4+T cells with resul-
tant release of IFN- γ which activates macrophages. 
While macrophages release cytokines, they trigger 
inflammation, and induce fibrosis. CD4+ T cells ef-
fect vascular endothelium and induce expression of 
adhesion molecules, and secretion of cytokine like 
TNF,  which  increases  production  of  chemokines. 
Response to cytokines produced by CD4+ T cells 
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T cells involve in the induction of fibrotic reaction 
in acute, and chronic destructive processes in kid-
neys, and in immune complex-mediated glomeru-
lopathies. Three mechanisms of these processes 
have been demonstrated in various studies. Firstly, 
T cells directly affect TGFβ, and renal fibroblasts 
with resultant migration, proliferation, and also dif-
ferentiation of renal fibroblasts into myofibroblasts. 
They effect macrophage population in the affected 
site, and induce transformation of some profibrotic 
cytokines  (platelet-derived  growth  factor  (PDGF),   
TGFβ 1 , and CTGF) and fibroblastlas into myofi-
broblasts. Thirdly, they directly affect tubular epithe-
lial cells together with growth factors, and cytokines 
in order to stimulate fibroblasts.15 Myofibroblasts are 
cellular  mediators  of  fibrosis.  Normally,  myofibro-
blasts do not exist in tubulointerstitial region. Fol-
lowing tissue damage, together with macrophages, 
myofibroblasts originating from mesenchymal cells 
start  to  accumulate  within  tissues  in  response  to 
TGFβ, PDGF and connective tissue growth factor 
(CTGF) factors and alike. Besides, they play a role 
in many types of leucocytes, and formation of fibro-
sis in the parenchymal tissue.16
Urinary tract infection is an important cause of 
infection in that they lead to the formation of scar 
tissue, secondary hypertension, and chronic kidney 
damage in children. As an outcome of infections, 
tubular  epithelial  dysfunction  develops,  fibrogenic 
cytokines are released, and inflammatory cells mi-
grate into kidneys.17,18
As  is  the  case  with  all  parenchymal  organs, 
TGFβ 1 is the most important cytokine in the de-
velopment of fibrosis. Another important immuno-
logical pathway in both dermal and renal fibrosis in-
volves toll-like receptors (TLRs) on fibroblasts and 
their ligands. TLRs are functionary components of 
the innate immune system. Fibroblasts in various 
tissues are known to express TLRs. Especially, the 
importance of increased TLR4 expression and its 
inducive function in the release of pro-inflammatory 
cytokines is already acknowledged.19
In the absence of TLR4, or in case of a genetic 
defect,  production  of  antimicrobial  peptides,  and 
accumulation rate of neutrophils decrease. When 
compared  with  normal  skin,  increased  TLR4  ex-
pression was observed in dermal atrophic scars.19
In  this  study,  assuming  similar  development 
mechanisms for all scar types, we aimed to inves-
tigate the correlation between size of a BCG scar, 
and development of renal scar. If any correlation is 
established, then presence and size of a BCG scar 
can be used as a determinative marker in the de-
velopment of renal scar. However, any correlation 
between the size of a BCG scar, and the presence 
of renal scar was not found.
In the development of renal scar secondary to 
acute pyelonephritis, immune state of the patient, 
especially his/her innate immunity is an important 
determinative factor. Besides, some polymorphisms 
involving in the development of scar formation have 
been  described.  Egyptian  pediatric  patients  with 
pyelonephritis  were  compared  with  healthy  con-
trols, and two TGFβ 1, and two vascular endothe-
lial growth factor (VEGF) variants were identified.20 
Similarly, in Irish children TGFβ 1, and VEGF vari-
ants were detected.21 Another limitation of our study, 
just as is the case with cytokine polymorphisms, we 
did not know TLR4 levels in groups with or without 
development  of  renal  scar.  In  our  patient  group, 
presence of any polymorphism is not known. This 
phenomenon might affect the results of our study.
In conclusion, development of a scar is a pro-
cess resulting from complex interactions between 
cells  and  cytokine  release.  For  the  mechanism 
of scar formation, which is thought to result from 
similar  cellular  mechanisms  and  mutual  cytokine 
release, to be able to delineate the association be-
tween formation of BCG scar and renal scar? Fur-
ther large-scale investigations with greater number 
of populations are needed.
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